-
Mashup Score: 37The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy - 1 month(s) ago
Eleftheria Kampouri, Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal, Terry L Stevens-Ayers, Damian J Green, Jordan Gauthier, Mazyar Shadma
Source: ashpublications.orgCategories: General Medicine NewsTweet
-
Mashup Score: 40T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy - 1 month(s) ago
Key Points. Based on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (G
Source: ashpublications.orgCategories: General Medicine NewsTweet-
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy https://t.co/FjXme7rKaK Severe (Grade 3+) T-ICAHT is strongly associated with increased transfusion burden and inferior survival following CAR T-cell therapy.
-
-
Mashup Score: 12Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study - 1 month(s) ago
Key Points. Bridging radiotherapy prior to CAR-T was well-tolerated with minimal toxicity in this large multicenter studyComprehensive bridging radiotherap
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study https://t.co/TFtJqdnyvW
-
-
Mashup Score: 4Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL - 1 month(s) ago
Key Points. A phase 2 academic clinical trial of CD19 CAR T cells demonstrates durable remissions with a 1-year LFS in low disease burden groups of >90%
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL https://t.co/SMOhjFlP1c
-
-
Mashup Score: 40T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy - 1 month(s) ago
Key Points. Based on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (G
Source: ashpublications.orgCategories: General Medicine NewsTweet-
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy https://t.co/FjXme7rKaK Severe (Grade 3+) T-ICAHT is strongly associated with increased transfusion burden and inferior survival following CAR T-cell therapy.
-
-
Mashup Score: 1Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma - 1 month(s) ago
Key Points. Maintenance romidepsin post-AHCT in an unselected population of patients with PTCL did not meet a primary efficacy endpoint.Maintenance romidep
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma https://t.co/PJ15zZv7tX
-
-
Mashup Score: 30Immunological Consequences of CAR T-Cell Therapy - Analysis of Infectious Complications and Immune Reconstitution - 1 month(s) ago
Key Points. CAR T-cells induce a cellular and humoral immunodeficiency resulting in an initial susceptibility for bacterial and later viral infectionsSever
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Immunological Consequences of CAR T-Cell Therapy - Analysis of Infectious Complications and Immune Reconstitution https://t.co/1fbZvUt0ZR
-
-
Mashup Score: 3Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Initial Response to Intensive Chemotherapy Induction - 1 month(s) ago
Key Points. No clearance of mid-cycle-marrow blasts in patients with IDH2R172-mutated AML after intensive induction, despite later achieving CRKinetics of
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Initial Response to Intensive Chemotherapy Induction https://t.co/GtzFb0KmwP
-
-
Mashup Score: 12Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study - 1 month(s) ago
Key Points. Bridging radiotherapy prior to CAR-T was well-tolerated with minimal toxicity in this large multicenter studyComprehensive bridging radiotherap
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study https://t.co/TFtJqdnyvW
-
-
Mashup Score: 37The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy - 1 month(s) ago
Eleftheria Kampouri, Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal, Terry L Stevens-Ayers, Damian J Green, Jordan Gauthier, Mazyar Shadma
Source: ashpublications.orgCategories: General Medicine NewsTweet-
The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy https://t.co/nGZADTBxvf
-
The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy https://t.co/nGZADTBxvf